J&J, Evotec partner on ectodomain shedding drug discovery project

By Jenni Spinner contact

- Last updated on GMT

(Rost-9D/iStock via Getty Images Plus)
(Rost-9D/iStock via Getty Images Plus)

Related tags: Janssen, Johnson & johnson, Drug discovery, biotech, Drug development

Janssen has formed a strategic collaboration with the drug discovery specialist that involves applying TargetAlloMod platforms to protein homeostasis.

Janssen’s partnership reportedly builds on Evotec’s discovery that small molecules can bind allosterically to certain extracellular receptors and induce a natural proteolytic cleavage process to shed the ectodomain.

 “The shedding of the ectodomain of a membrane protein will have a variety of effects dependent on the specific target and the role it plays in normal and disease pathology. For example, the shedding of a protein that is involved in a ligand-driven cellular signaling will lead to a cessation of signaling by that particular pathway​,” said a spokesperson for Evotec.

As well as disrupting cell signaling, the process can lead to the shed ectodomain acting as a sink for the native ligand of the targeted receptor. The potential for the approach to unlock first-in-class novel modes of action has attracted Janssen, which agreed to pay Evotec research funding and success-based research and commercial milestones of up to approximately €210m ($215m) per project.

In return, Janssen has gained the chance to jointly conduct screens on the identified targets with Evotec. The partners will collaborate on hit identification and lead optimization of the most promising chemical assets.

The collaboration will use a suite of proprietary assay principles and computational tools, TargetAlloMod, that Evotech has created to screen extracellular receptor targets for the induction of shedding by small molecule allosteric modulators. TargetAlloMod represents a different approach to drug discovery.

The shedding-based approach to drug discovery is different from conventional approaches to target cell surface receptors such as neutralizing antibodies in that it follows an event-driven paradigm rather than occupancy driven. As such one shedding activator molecule may lead to the shedding of many molecules of its target cell surface protein​,” the spokesperson said.

Evotec’s spokesperson declined to say why the TargetAlloMod platforms are a good fit for the Janssen project, explaining that it is one of the company’s “core principles not to comment on partnered projects without prior approval from the respective partner or partners​.”

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 15-Aug-2022 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Related suppliers

Follow us

Products

View more

Webinars